Database Query Results : , ,

CLL, Chronic Lymphocytic Leukemia: Click to Expand ⟱
CLL is a type of cancer that affects the lymphoid cells, which are a type of white blood cell. It is characterized by the accumulation of mature, but dysfunctional, lymphocytes in the bone marrow, lymph nodes, and spleen. CLL is typically a slow-growing disease, and many patients may not experience symptoms for years after diagnosis.
Scientific Papers found: Click to Expand⟱
1249- CHr,    Chrysin as an Anti-Cancer Agent Exerts Selective Toxicity by Directly Inhibiting Mitochondrial Complex II and V in CLL B-lymphocytes
- in-vitro, CLL, NA
ROS↑, MMP↓, ADP:ATP↑, Casp3↑, Apoptosis↑,
1843- dietFMD,  BTZ,    Cyclic Fasting–Mimicking Diet Plus Bortezomib and Rituximab Is an Effective Treatment for Chronic Lymphocytic Leukemia
- in-vivo, CLL, NA
AntiTum↓, Apoptosis↑, IGF-1↓, eff↑, OS↑, eff↑,
652- EGCG,  VitK2,  CUR,    Case Report of Unexpectedly Long Survival of Patient With Chronic Lymphocytic Leukemia: Why Integrative Methods Matter
- Case Report, CLL, NA
Remission↑,
653- EGCG,    Phase 2 Trial of Daily, Oral Polyphenon E in Patients with Asymptomatic, Rai Stage 0-II Chronic Lymphocytic Leukemia(CLL)
- Trial, CLL, NA
ALC↓, Remission↑,
1286- HNK,    The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells
- in-vitro, CLL, NA
Apoptosis↑, Casp3↑, Casp8↑, Casp9↑, cl‑PARP↑, Bcl-2↓, BAX↑,
4648- OLEC,    The Effect of Dietary Intervention With High-Oleocanthal and Oleacein Olive Oil in Patients With Early-Stage Chronic Lymphocytic Leukemia: A Pilot Randomized Trial
- Trial, CLL, NA
Apoptosis↑, *QoL↑,
4953- PEITC,    PEITC: a natural compound effective in killing primary leukemia cells and overcoming drug resistance
- in-vitro, CLL, NA
ROS↑, GSH↓, TumCD↓, eff↓, Mcl-1↓, Casp3↑,
1255- PI,  ALA,    Antileukemic effects of piperlongumine and alpha lipoic acid combination on Jurkat, MEC1 and NB4 cells in vitro
- in-vitro, CLL, NA
COX2↓, Casp3↑,
2592- VitC,    Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line
- in-vitro, CLL, NA
NRF2↓, GSH↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 9

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↓, 2,   NRF2↓, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↑, 1,   MMP↓, 1,  

Cell Death ⓘ

Apoptosis↑, 4,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 4,   Casp8↑, 1,   Casp9↑, 1,   Mcl-1↓, 1,   TumCD↓, 1,  

DNA Damage & Repair ⓘ

cl‑PARP↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

IGF-1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↓, 1,   eff↑, 2,  

Clinical Biomarkers ⓘ

ALC↓, 1,  

Functional Outcomes ⓘ

AntiTum↓, 1,   OS↑, 1,   Remission↑, 2,  
Total Targets: 22

Pathway results for Effect on Normal Cells:


Functional Outcomes ⓘ

QoL↑, 1,  
Total Targets: 1

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:50  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page